



Dear Patient:

Our center is taking part in a new study, FLoW by Novo Nordisk, for patients with type II diabetes and chronic kidney disease. When patients have type II diabetes it can cause many different health problems, such as chronic kidney disease. A completed study showed that a medicine called semaglutide might improve diabetic kidney disease outcomes.

The main purpose of the FLoW study is to look how well semaglutide works, when compared to placebo, in slowing the progression of diabetic kidney disease. Semaglutide, the study medication, is one that is already FDA-approved for the treatment of type II diabetes in the US. The trade name of this medication is Ozempic® and is a once weekly, non-insulin, injectable medication.

Approximately 3,160 adults from all over the world will take part in this study. You may be able to take part in the FLoW Study if you:

- are 18 years of age or older
- have type II diabetes mellitus
- have diabetic kidney disease
- are not currently on dialysis

The study will last between 3 and 5 years. You will have up to 17 clinic visits and 11 phone call visits, however the trial does allow for alternative scheduling when needed. A screening visit would be done first to ensure that you meet all of the necessary safety criteria. If you qualify after the screening visit, you will begin the study medication at the second visit. If you do decide to take part in this study, all study medication, diabetic testing supplies and tests will be provided at no cost. It's important to note that taking part in a study will not impact the standard visits you have with your own healthcare providers. Our team will regularly update your doctor on your study status and we will also share copies of any labs or eye exams that are completed during the trial.

Please feel free to contact me if you have any questions, or if you would like to learn more about this study. If you contact me, you can still choose not to join the study.

Thank you,

Dr. Cynthia Bowman-Stroud, Principal Investigator &
Allie Guill, Lead Clinical Research Coordinator
270-441-4606 (or call/text 270-994-9926)